Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

A novel B7-H3-specific binder enables effective CAR T-cell therapy in an Acute Myeloid Leukemia experimental model

View Full Paper
Ask AI
Bookmark
Share

Authors

MVMichele VenerusoSMSimona ManniRCRoberta Castriconi

Discussion

Loading...

Member takes

Overview

Immunotherapy enhances clinical outcomes in acute myeloid leukemia, suggesting CAR T-cell targeting of B7-H3 is effective.

Key Points

  • Evaluate the therapeutic potential of B7-H3-targeted CAR T-cell therapy in acute myeloid leukemia.
  • Developed CAR constructs targeting B7-H3
  • Evaluated anti-leukemic activity using THP-1 cell line
  • Tested efficacy in an immunodeficient mouse model
  • CAR T-cells achieved over 65% expression in vitro after transduction
  • High efficacy against B7-H3+ THP-1 cells, reducing them to 0.14%
  • Improved overall survival in treated mice compared to controls, with 90% survival at 60 days

Cite This Study

Veneruso et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e144https://doi.org/10.1182/blood-2025-6095
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design2021 · 76 citations
  2. 2Non-hematotoxic Tim-3/CD70 dual-targeting CAR T cells promote potent anti-leukemia activity against acute myeloid leukemia2025 · 1 citations
  3. 3The search for safe and effective CAR-T targets in AML2026 · 1 citations
  4. 4The Rise of Fine-Tuned CAR-Based Therapies Against Acute Myeloid Leukemia2025 · 7 citations
  5. 5Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations2024 · 17 citations